Xeris Biopharma Names John Shannon To Succeed Paul Edick As New CEO And Board Director

7/8/24 7:08:20 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $XERS alert in real time by email

The company announced a CEO succession plan effective August 1, 2024, under which Paul R. Edick will be retiring from his day-to-day operational and Chairman role at Xeris after more than seven years with the Company.

Pursuant to the Company's succession plan, the Board has appointed, John P. Shannon, Xeris' President and Chief Operating Officer, as the new CEO and a member of the Board of Directors.

Get the next $XERS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XERS

Date	Price Target	Rating	Analyst
11/11/2024	$3.00	Overweight → Neutral	Piper Sandler
3/28/2024	$5.00	Outperform	Oppenheimer
8/28/2023	$4.50	Buy	Craig Hallum
10/21/2022	$4.00	Buy	Jefferies
4/28/2022	$6.50	Buy	Craig Hallum
2/16/2022	$8.00 → $6.00	Outperform	SVB Leerink
12/31/2021	$6.00 → $8.00	Outperform	SVB Leerink
12/31/2021	$4.25 → $5.40	Buy	HC Wainwright & Co.

More analyst ratings

$XERS
Leadership Updates

Live Leadership Updates

Xeris Biopharma Announces CEO Succession Plan
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20
7/8/24 7:00:00 AM ET
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care
Xeris Biopharma Appoints Ricki Fairley to Board of Directors
Xeris Biopharma Holdings (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, appointed Ricki Fairley to its Board of Directors, increasing the size of the Board to nine members, on March 27, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005369/en/(Photo: Business Wire) "On behalf of our Board, we welcome Ricki and her wealth of insights and experiences, especially her passion for advocating on behalf of patients," said Paul R. Edick, Chairman and Chief Executive Officer of Xeris. "As
3/29/23 4:05:00 PM ET
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care
IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
1/27/21 8:00:00 AM ET
$CLGN
$UTHR
$XERS
Industrial Specialties
Health Care
Biotechnology: Pharmaceutical Preparations

$XERS
Financials

Live finance-specific insights

Xeris Biopharma Reports Third Quarter 2024 Financial Results
Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quarter Ended Q3 with $69.4M in cash, cash equivalents and short-term investments Raises full-year guidance of total net revenue to $198M-$202M and tightens year-end cash to $68M-$72M Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30,
11/8/24 7:00:00 AM ET
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Friday, November 8, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=6c5018a9&confId=72180. Afte
10/31/24 8:00:00 AM ET
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care
Xeris Biopharma Reports Second Quarter 2024 Financial Results
Achieved revenue of $48.1M including record product revenue of $46.5M Total revenues increased 18% over the prior quarter and 26% over the same period prior year Ended Q2 with $77.6M in cash, cash equivalents and short-term investments Tightens full-year 2024 guidance: total net revenue to $190M-$200M and year-end cash balance to $60M-$75M John Shannon appointed CEO and Kevin McCulloch promoted to President and COO per the Company's long-standing succession plan Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing inno
8/8/24 7:00:00 AM ET
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care

$XERS
Press Releases

Fastest customizable press release news feed in the world

Xeris to Participate in Upcoming Investor Conferences
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 1x1 meetings and fireside chat February 12, 2025 at 1:20 pm ET Leerink Global Healthcare Conference, Miami, FL 1x1 meetings and fireside chat on March 10, 2025 at 8:40 am ET Barclays 27th Annual Global Healthcare Conference, Miami, FL 1x1 meetings only on March 11, 2025 Please check with each co
2/5/25 8:00:00 AM ET
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with
1/21/25 9:00:00 AM ET
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially 2024 financial results and 2025 outlook expected on March 6, 2025 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equiv
1/10/25 7:00:00 AM ET
$XERS
Biotechnology: Pharmaceutical Preparations
Health Care

Xeris Biopharma Names John Shannon To Succeed Paul Edick As New CEO And Board Director

Chat with this insight

Recent Analyst Ratings for $XERS

$XERS Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

SEC Form SC 13G/A filed by Xeris Biopharma Holdings Inc. (Amendment)

SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

$XERS Leadership Updates

Live Leadership Updates

Xeris Biopharma Announces CEO Succession Plan

Xeris Biopharma Appoints Ricki Fairley to Board of Directors

IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors

$XERS SEC Filings

Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$XERS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Schmid John P. bought $10,147 worth of shares (4,515 units at $2.25) (SEC Form 4)

Director Schmid John P. bought $10,134 worth of shares (4,285 units at $2.37) (SEC Form 4)

Schmid John P. bought $10,314 worth of shares (5,400 units at $1.91) (SEC Form 4)

$XERS Financials

Live finance-specific insights

Xeris Biopharma Reports Third Quarter 2024 Financial Results

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Xeris Biopharma Reports Second Quarter 2024 Financial Results

$XERS Press Releases

Fastest customizable press release news feed in the world

Xeris to Participate in Upcoming Investor Conferences

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

$XERS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Mcculloch Kevin covered exercise/tax liability with 78,134 shares and was granted 185,000 shares, increasing direct ownership by 7% to 1,684,318 units (SEC Form 4)

Officer Shannon John Patrick Jr covered exercise/tax liability with 221,500 shares and was granted 800,000 shares, increasing direct ownership by 27% to 2,687,118 units (SEC Form 4)

Officer Hecht Beth covered exercise/tax liability with 144,284 shares and was granted 185,000 shares, increasing direct ownership by 3% to 1,393,510 units (SEC Form 4)

$XERS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Xeris Biopharma downgraded by Piper Sandler with a new price target

Oppenheimer initiated coverage on Xeris Biopharma with a new price target

Craig Hallum initiated coverage on Xeris Biopharma with a new price target

Recent Analyst Ratings for
$XERS

$XERS
Large Ownership Changes

$XERS
Leadership Updates

$XERS
SEC Filings

$XERS
Insider Purchases

$XERS
Financials

$XERS
Press Releases

$XERS
Insider Trading

$XERS
Analyst Ratings